No connection

Search Results

KPTI vs KRRO

KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%
KRRO
Korro Bio, Inc.
BEARISH
Price
$12.68
Market Cap
$182.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
KPTI
--
KRRO
--
Forward P/E
KPTI
-1.83
KRRO
-1.67
P/B Ratio
KPTI
-0.5
KRRO
2.32
P/S Ratio
KPTI
1.23
KRRO
28.61
EV/EBITDA
KPTI
-4.3
KRRO
-1.82

Profitability

Gross Margin
KPTI
9.93%
KRRO
0.0%
Operating Margin
KPTI
-52.36%
KRRO
-1229.33%
Profit Margin
KPTI
-134.21%
KRRO
0.0%
ROE
KPTI
--
KRRO
-110.7%
ROA
KPTI
-41.56%
KRRO
-32.14%

Growth

Revenue Growth
KPTI
11.6%
KRRO
-43.1%
Earnings Growth
KPTI
--
KRRO
--

Financial Health

Debt/Equity
KPTI
--
KRRO
0.85
Current Ratio
KPTI
1.12
KRRO
6.9
Quick Ratio
KPTI
0.98
KRRO
6.38

Dividends

Dividend Yield
KPTI
--
KRRO
--
Payout Ratio
KPTI
0.0%
KRRO
0.0%

AI Verdict

KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
KRRO BEARISH

KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.

Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)

Compare Another Pair

KPTI vs KRRO: Head-to-Head Comparison

This page compares Karyopharm Therapeutics Inc. (KPTI) and Korro Bio, Inc. (KRRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile